115 years of building, sharing and reinvesting in knowledge
A rich
legacy
Founded in 1908 and headquartered in Denmark, we are majority owned by the LEO Foundation
Medical dermatology
Dedicating decades of research and development to advance the science of dermatology
Our
purpose
Advancing the standard of care for the benefit of people with skin conditions, their families and society
Our performance and results
LEO Pharma's Annual Report covers our financial and sustainability reporting for the financial year from January 1 to December 31.
Read our 2023 Annual Report
NEWS ARTICLE
LEO Pharma delivers 11% revenue growth (CER) in H1 and upgrades financial outlook for the year
During the first six months of 2024, LEO Pharma continued to execute on its strategy with the dermatology portfolio as the primary growth driver. With revenue growth of 11% in constant exchange rates (CER) and EBITDA margin of 9% in the first half of the year, LEO Pharma remains on course to deliver solid financial performance for the full year and the financial outlook has been updated accordingly.
Ballerup, Denmark, August 26, 2024
2024 Six-month interim report
CAREER
Discover how we innovate collectively.
For us, collaborating innovatively means continuously enhancing and expanding what's achievable for one another, our company, and our patients.
Learn more
